ACR Convergence 2025| Video: Rheuminations on Milestones & Ageism

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: chronic pain

Is an Arthritis Vaccine Using Genetically Reprogrammed Stem Cells on the Horizon?

Elizabeth Hofheinz, MPH, MEd  |  August 13, 2017

The words genetically modified are making people run for the hills these days. Not so when it comes to arthritis care, however. In the lab of one pioneering researcher, genetic engineering is catapulting arthritis treatment years ahead. Farshid Guilak, PhD, is a professor in the Department of Orthopaedic Surgery at Washington University, St. Louis, and…

Filed under:ConditionsResearch Rheum Tagged with:anti-inflammatory drugArthritisgeneticinflammationResearchRheumatic Diseaserheumatologystem cellvaccine

New Hampshire Sues Purdue Pharma over Opioid Marketing

Nate Raymond  |  August 8, 2017

(Reuters)—New Hampshire sued OxyContin maker Purdue Pharma LP on Tuesday, joining several state and local governments in accusing the drugmaker of engaging in deceptive marketing practices that have helped fuel a national opioid addiction epidemic. The lawsuit filed in Merrimack County Superior Court claimed that Purdue Pharma significantly downplayed the risk of addiction posed by…

Filed under:AnalgesicsDrug UpdatesLegal Updates Tagged with:lawsuitLegalOpioid abuseopioid crisisOpioidsOxyContinpharmaceutical companyPurdue Pharma LP

Progress Made During HOD Annual Meeting

Gary L. Bryant, MD, FACR, FACP  |  July 24, 2017

The AMA House of Delegates (HOD) met in Chicago for its annual meeting June 9–14. More than 530 HOD members were present, with several hundred AMA and association staff and guests. As I am sure you have noted from past issues of ACR@Work, the ACR is in its five-year membership review. The ACR must be…

Filed under:Legislation & AdvocacyProfessional Topics Tagged with:AMA annual meetingAMA House of Delegates (HOD)AMA membership

Amyloidosis Is Often Underdiagnosed, Undertreated

Lara C. Pullen, PhD  |  July 14, 2017

CHICAGO—Caryn A. Libbey, MD, clinical associate professor of medicine at Boston University School of Medicine, described the evolving in our understanding of amyloid at the ACR’s State-of-the-Art Clinical Symposium in April. Amyloidosis is a rare disease that is often underdiagnosed and undertreated. “Even though this disease has been around for 150 years, I still consider it…

Filed under:ConditionsMeeting ReportsOther Rheumatic ConditionsResearch Rheum Tagged with:2017 State of the Art Clinical SymposiumAC&RAmerican College of Rheumatology (ACR)AmyloidosisDiagnosisinflammatory syndromepatient careResearchRheumatic DiseaserheumatologyTreatment

Essential Collaboration: Rheumatologists & PTs Must Work Together

Richard Quinn  |  July 14, 2017

The importance of rheumatologists and physical therapists (PTs) working together for patients cannot be understated. Carol Oatis, PT, PhD, says, “Rheumatologists and PTs have very similar goals. … Collaboration is essential for optimal outcomes.”…

Filed under:Practice SupportProfessional Topics Tagged with:ExerciseExercise/physical therapyphysical therapistPhysical Therapyrheumatologist

ARHP Clinical Focus Course Targets Management of Adults with SLE

Maura Iversen  |  July 13, 2017

This year the ARHP Clinical Focus Course brings together experts in the field to provide an interprofessional approach to the management of systematic lupus erythematosus (SLE) to improve patient outcomes. The daylong course, titled Systemic Lupus Erythematosus: Taming the Wolf—Salient Lessons from Practice and Research, which is offered on Nov. 4, will provide a case-based…

Filed under:ConditionsMeeting ReportsProfessional TopicsSystemic Lupus Erythematosus Tagged with:2017 ACR/ARHP Annual MeetingAssociation of Rheumatology Professionals (ARP)ClinicalEducationhealth professionalsinterprofessionalLupusManagementmultidisciplinarypatient carerheumatologistrheumatologySLETreatment

How to Document a Patient’s Medical History

From the College  |  July 13, 2017

The levels of service within an evaluation and management (E/M) visit are based on the documentation of key components, which include history, physical examination and medical decision making. The history component is comparable to telling a story and should include a beginning and some form of development to adequately describe the patient’s presenting problem. To…

Filed under:Billing/CodingFrom the CollegePractice Support Tagged with:BillingCenters for Medicare & Medicaid Services (CMS)CodingDocumentationguidelineoffice visitpatient carephysicianpractice management. evaluationReimbursementrheumatologistrheumatology

FDA Responds to New Drug Application for Baricitinib

Michele B. Kaufman, PharmD, BCGP  |  June 15, 2017

Oxycodone Tablets Submitted to FDA Filings for oxycodone tablets (Oxaydo) in both 10 and 15 mg doses have been accepted by the U.S. Food and Drug Administration (FDA).1 The submission is based on a pharmacokinetic study demonstrating bioequivalence to the reference drug, oxycodone hydrochloride (Roxicodone) tablets at a 15 mg dose. The product is an…

Filed under:AnalgesicsConditionsDrug Updates Tagged with:analgesicApprovalsbaricitinibDisease-modifying antirheumatic drugs (DMARDs)drugFDAopioidOxycodonepsoriatic arthritisQualityRARheumatoid arthritisSafetysecukinumabupdate

U.S. State Attorneys General Probe Opioid Drug Companies

Nate Raymond  |  June 15, 2017

(Reuters)—A bipartisan group of state attorneys general announced on Thursday that they are jointly investigating the marketing and sales practices of drug companies that manufacture opioid painkillers at the center of a national addiction epidemic. Attorneys general from states including Massachusetts, Texas, Illinois and Pennsylvania announced the investigation two weeks after Ohio Attorney General Mike…

Filed under:Legal UpdatesProfessional Topics Tagged with:Allergan Plc.Endo International PlcJohnson and Johnsonnational addiction epidemicopioid drug companiesOpioid probePurdue Pharma LPTeva Pharmaceutical Industries Ltd’s Cephalon

The Birth and Growth of Biotechnology, and the Impact of Biologic Drugs on Rheumatology

Simon M. Helfgott, MD  |  June 15, 2017

Here’s a trivia question: Where were the big ideas for the field of biotechnology first discussed? Answer: At a since-demolished delicatessen in Waikiki Beach, Hawaii. Go figure. The year was 1972, and Stanley Cohen, MD, professor of medicine at Stanford University in Palo Alto, Calif., and Herbert Boyer, PhD, a former professor and biochemist at the…

Filed under:Biologics/DMARDsOpinionResearch RheumRheuminationsSpeak Out Rheum Tagged with:BiologicsBiosimilarsbiotechnologyCongressDNAdrug costdrug therapypatient careResearchRheumatic DiseaserheumatologistrheumatologyTreatment

  • « Previous Page
  • 1
  • …
  • 73
  • 74
  • 75
  • 76
  • 77
  • …
  • 109
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences